MedTrace Logo

Trial to Optimally Show the Pharmacological Action of Z-100

NCT03476018 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2022-06-16

No results posted yet for this study

Summary

The objective of this clinical trial is to evaluate the change of the immunological parameter levels in FIGO stage IIIB cervical cancer subjects by administration of Z-100

Conditions

Interventions

DRUG

Z-100

Twice a week until 29 days after completion of chemoradiotherapy, then once every 14 days

DRUG

Placebos

Twice a week until 29 days after completion of chemoradiotherapy, then once every 14 days

Sponsors & Collaborators

  • Zeria Pharmaceutical

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
79 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-02
Primary Completion
2021-07-20
Completion
2021-12-10

Countries

  • Vietnam

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03476018 on ClinicalTrials.gov